Cargando…

Weight Reduction by the Low-Insulin-Method—A Randomized Controlled Trial

Continuous high insulin levels are associated with weight gain and lead to cardiometabolic diseases. Therefore, we have developed the Low-Insulin-Method and integrated it into the multi-component, occupational healthcare program SHAPE-AND-MOTION-Medical-Accompanied-Slimming (SAMMAS) to reduce daily...

Descripción completa

Detalles Bibliográficos
Autores principales: Röhling, Martin, Martin, Katharina, Ellinger, Sabine, Schreiber, Michael, Martin, Stephan, Kempf, Kerstin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7601801/
https://www.ncbi.nlm.nih.gov/pubmed/33007918
http://dx.doi.org/10.3390/nu12103004
_version_ 1783603518674829312
author Röhling, Martin
Martin, Katharina
Ellinger, Sabine
Schreiber, Michael
Martin, Stephan
Kempf, Kerstin
author_facet Röhling, Martin
Martin, Katharina
Ellinger, Sabine
Schreiber, Michael
Martin, Stephan
Kempf, Kerstin
author_sort Röhling, Martin
collection PubMed
description Continuous high insulin levels are associated with weight gain and lead to cardiometabolic diseases. Therefore, we have developed the Low-Insulin-Method and integrated it into the multi-component, occupational healthcare program SHAPE-AND-MOTION-Medical-Accompanied-Slimming (SAMMAS) to reduce daily insulin levels for long-term weight reduction in overweight or obesity. Employees were randomized into a starting intervention group (SI, n = 15) or waiting list control group (WL, n = 15). SAMMAS consisted of group-based seminars, low-carbohydrate nutrition including formula diet, continuous glucose monitoring, telemetric monitoring, and telemedical coaching. Both groups received telemetric devices at baseline. Intention-to-treat analyses were performed after 12, 26, and 52 weeks. The estimated treatment difference in weight reduction after 12 weeks, which is the primary endpoint of the study, showed a pronounced effect in favour of SI (−6.3 kg with (95% confidence interval) (−7.4; −4.5) (p < 0.001)) after 12 weeks. Furthermore, SI improved fasting blood glucose, HbA1c, quality of life, fasting insulin, blood pressure, and eating behaviour (all p < 0.05) in the within-group analysis, while WL did not. After 26 and 52 weeks, weight reduction could be maintained in the whole group (both groups together) by −6.7 kg (−9.5; −3.8) (p < 0.001) and −6.1 kg (−9.2; −2.7) (p < 0.01). SAMMAS supports clinically relevant weight reduction and long-term weight loss maintenance in individuals with overweight or obesity.
format Online
Article
Text
id pubmed-7601801
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-76018012020-11-01 Weight Reduction by the Low-Insulin-Method—A Randomized Controlled Trial Röhling, Martin Martin, Katharina Ellinger, Sabine Schreiber, Michael Martin, Stephan Kempf, Kerstin Nutrients Article Continuous high insulin levels are associated with weight gain and lead to cardiometabolic diseases. Therefore, we have developed the Low-Insulin-Method and integrated it into the multi-component, occupational healthcare program SHAPE-AND-MOTION-Medical-Accompanied-Slimming (SAMMAS) to reduce daily insulin levels for long-term weight reduction in overweight or obesity. Employees were randomized into a starting intervention group (SI, n = 15) or waiting list control group (WL, n = 15). SAMMAS consisted of group-based seminars, low-carbohydrate nutrition including formula diet, continuous glucose monitoring, telemetric monitoring, and telemedical coaching. Both groups received telemetric devices at baseline. Intention-to-treat analyses were performed after 12, 26, and 52 weeks. The estimated treatment difference in weight reduction after 12 weeks, which is the primary endpoint of the study, showed a pronounced effect in favour of SI (−6.3 kg with (95% confidence interval) (−7.4; −4.5) (p < 0.001)) after 12 weeks. Furthermore, SI improved fasting blood glucose, HbA1c, quality of life, fasting insulin, blood pressure, and eating behaviour (all p < 0.05) in the within-group analysis, while WL did not. After 26 and 52 weeks, weight reduction could be maintained in the whole group (both groups together) by −6.7 kg (−9.5; −3.8) (p < 0.001) and −6.1 kg (−9.2; −2.7) (p < 0.01). SAMMAS supports clinically relevant weight reduction and long-term weight loss maintenance in individuals with overweight or obesity. MDPI 2020-09-30 /pmc/articles/PMC7601801/ /pubmed/33007918 http://dx.doi.org/10.3390/nu12103004 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Röhling, Martin
Martin, Katharina
Ellinger, Sabine
Schreiber, Michael
Martin, Stephan
Kempf, Kerstin
Weight Reduction by the Low-Insulin-Method—A Randomized Controlled Trial
title Weight Reduction by the Low-Insulin-Method—A Randomized Controlled Trial
title_full Weight Reduction by the Low-Insulin-Method—A Randomized Controlled Trial
title_fullStr Weight Reduction by the Low-Insulin-Method—A Randomized Controlled Trial
title_full_unstemmed Weight Reduction by the Low-Insulin-Method—A Randomized Controlled Trial
title_short Weight Reduction by the Low-Insulin-Method—A Randomized Controlled Trial
title_sort weight reduction by the low-insulin-method—a randomized controlled trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7601801/
https://www.ncbi.nlm.nih.gov/pubmed/33007918
http://dx.doi.org/10.3390/nu12103004
work_keys_str_mv AT rohlingmartin weightreductionbythelowinsulinmethodarandomizedcontrolledtrial
AT martinkatharina weightreductionbythelowinsulinmethodarandomizedcontrolledtrial
AT ellingersabine weightreductionbythelowinsulinmethodarandomizedcontrolledtrial
AT schreibermichael weightreductionbythelowinsulinmethodarandomizedcontrolledtrial
AT martinstephan weightreductionbythelowinsulinmethodarandomizedcontrolledtrial
AT kempfkerstin weightreductionbythelowinsulinmethodarandomizedcontrolledtrial